Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calcipotriol + fumaric acid esters
- Development stage
- Unknown
- Lead developer
- LEO Pharma
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
A combination therapy consisting of topical calcipotriol (a vitamin D analog) and oral fumaric acid esters (FAEs) for the treatment of psoriasis. This combination has been shown to be significantly more effective and faster acting than FAE monotherapy in treating severe plaque psoriasis. The combination also demonstrates an FAE-sparing effect, allowing for lower doses of FAEs while maintaining efficacy, thus providing a superior benefit/risk ratio.
02
Targets
VDR (Vitamin D receptor)NF-κB
Beyond the preview
Go deeper on calcipotriol + fumaric acid esters.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calcipotriol + fumaric acid esters.